Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 69.3% in December

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 76,618 shares, a growth of 69.3% from the November 30th total of 45,256 shares. Based on an average trading volume of 124,838 shares, the short-interest ratio is currently 0.6 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 124,838 shares, the short-interest ratio is currently 0.6 days.

Institutional Investors Weigh In On Kamada

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Simplicity Wealth LLC purchased a new position in Kamada in the 3rd quarter valued at about $70,000. Trexquant Investment LP bought a new stake in shares of Kamada during the 1st quarter valued at about $82,000. Man Group plc acquired a new stake in shares of Kamada during the 3rd quarter worth approximately $199,000. Cubist Systematic Strategies LLC acquired a new stake in Kamada in the first quarter worth $206,000. Finally, Jump Financial LLC acquired a new stake in shares of Kamada in the 2nd quarter worth about $219,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Stock Down 0.3%

Shares of NASDAQ KMDA traded down $0.02 on Monday, hitting $7.05. The company had a trading volume of 27,481 shares, compared to its average volume of 100,102. Kamada has a 12-month low of $5.54 and a 12-month high of $9.15. The firm has a market capitalization of $405.41 million, a P/E ratio of 19.58, a PEG ratio of 0.75 and a beta of 0.92. The business has a 50 day moving average of $6.94 and a two-hundred day moving average of $7.13.

Kamada (NASDAQ:KMDA) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The company had revenue of $47.01 million for the quarter, compared to analysts’ expectations of $154.21 million. On average, sell-side analysts anticipate that Kamada will post 0.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Finally, HC Wainwright raised their price objective on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.